Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 5,8-dihydro-2,4-dimethyl-8-((2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)pyrido(2,3-d)pyrimidin-7(6h)-one
2. Ana 756
3. Ana-756
4. Ana756
5. Taso-sartan
1. 145733-36-4
2. Ana-756
3. Way-ana-756
4. 2,4-dimethyl-8-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]-5,6-dihydropyrido[2,3-d]pyrimidin-7-one
5. Chembl432162
6. 48g92v856h
7. Verdia
8. 2,4-dimethyl-8-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]-5,6-dihydropyrido[6,5-d]pyrimidin-7-one
9. 5,8-dihydro-2,4-dimethyl-8-((2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)pyrido(2,3-d)pyrimidin-7(6h)-one
10. Taso-sartan
11. 8-((2'-(1h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2,4-dimethyl-5,8-dihydropyrido[2,3-d]pyrimidin-7(6h)-one
12. Ana756
13. Tasosartan (usan/inn)
14. Tasosartan [usan:inn:ban]
15. Unii-48g92v856h
16. Ana 756
17. Way-126756
18. Ethylglycidylether
19. Tasosartan [mi]
20. Tasosartan [inn]
21. Tasosartan [usan]
22. Tasosartan [mart.]
23. Tasosartan [who-dd]
24. Schembl49626
25. Way-ana 756
26. Gtpl6898
27. Dtxsid40163148
28. Ex-a082
29. Chebi:135666
30. Act06754
31. Amy31168
32. Bcp06091
33. Hy-a0250
34. Bdbm50040439
35. Mfcd00865905
36. Zinc13444037
37. Akos000278114
38. Db01349
39. Ds-6574
40. Ncgc00390218-01
41. 5,8-dihydro-2,4-dimethyl-8-(p-(o-1h-tetrazol-5-ylphenyl)benzyl)pyrido(2,3-d)pyrimidin-7(6h)-one
42. Ac-35374
43. Db-042802
44. Cs-0017594
45. Ft-0631174
46. D06010
47. 733t364
48. A846571
49. L001443
50. J-524315
51. Q1317131
52. 2,4-dimethyl-8-({4-[2-(2h-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-5h,6h,7h,8h-pyrido[2,3-d]pyrimidin-7-one
53. 2,4-dimethyl-8-[2''-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8-dihydro-6h-pyrido[2,3-d]pyrimidin-7-one
54. 2,4-dimethyl-8-[2''-(2h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5,8-dihydro-6h-pyrido[2,3-d]pyrimidin-7-one
55. 2,4-dimethyl-8-[2'-(1h-tetrazol-5-yl)biphenyl-4-ylmethyl]-5,8-dihydro-6h-pyrido[2,3-d]pyrimidin-7-one
56. 2,4-dimethyl-8-{[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl}-5,8-dihydropyrido[2,3-d]pyrimidin-7(6h)-one
57. 5,8-dihydro-2,4-dimethyl-8-[[2'-(2h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-pyrido[2,3-d]pyrimidin-7(6h)-one
58. 5,8-dihydro-2,4-dimethyl-8-[[2'-(2h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]pyrido[2,3-d]pyrimidin-7(6h)-one
59. 8-((2'-(1h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2,4-dimethyl-5,6-dihydropyrido[2,3-d]pyrimidin-7(8h)-one
60. 8-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)-2,4-dimethyl-5,6-dihydropyrido[2,3-d]pyrimidin-7(8h)-one
61. Pyrido(2,3-d)pyrimidin-7(6h)-one, 5,8-dihydro-2,4-dimethyl-8-((2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-
62. Pyrido[2,3-d]pyrimidin-7(6h)-one, 5,8-dihydro-2,4-dimethyl-8-[[2'-(2h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
| Molecular Weight | 411.5 g/mol |
|---|---|
| Molecular Formula | C23H21N7O |
| XLogP3 | 3 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 4 |
| Exact Mass | 411.18075832 g/mol |
| Monoisotopic Mass | 411.18075832 g/mol |
| Topological Polar Surface Area | 101 Ų |
| Heavy Atom Count | 31 |
| Formal Charge | 0 |
| Complexity | 625 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Tasosartan is infrequently in the treatment of hypertension and heart failure.
By blocking the angiotensin II (AT1) receptor, the drug ultimately causes vasodilation, reduced secretion of vasopressin (ADH), reduced production and secretion of aldosterone, amongst other actions leading to the combined effect of a reduction of blood pressure.
Angiotensin II Type 1 Receptor Blockers
Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS. (See all compounds classified as Angiotensin II Type 1 Receptor Blockers.)
C - Cardiovascular system
C09 - Agents acting on the renin-angiotensin system
C09C - Angiotensin ii receptor blockers (arbs), plain
C09CA - Angiotensin ii receptor blockers (arbs), plain
C09CA05 - Tasosartan
Tasosartan has known human metabolites that include enoltasosartan.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
Tasosartan is a selective, potent, orally active and long-acting nonpeptide Angiotensin II type 1 (AT1) receptor antagonist. Tasosartan blocks the renin-angiotensin-aldosterone system (RAAS) at the level of the AT1 receptor that mediates most, if not all, of the important actions of Ang II. Tasosartan binds reversibly to the AT1 receptors in vascular smooth muscle and the adrenal gland. As angiotensin II is a vasoconstrictor, which also stimulates the synthesis and release of aldosterone, blockage of its effects results in decreases in systemic vascular resistance. AT1 receptor antagonists avoid the nonspecificity of the Ang I converting enzyme (ACE) inhibitors.
INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
A Tasosartan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tasosartan, including repackagers and relabelers. The FDA regulates Tasosartan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tasosartan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Tasosartan supplier is an individual or a company that provides Tasosartan active pharmaceutical ingredient (API) or Tasosartan finished formulations upon request. The Tasosartan suppliers may include Tasosartan API manufacturers, exporters, distributors and traders.
click here to find a list of Tasosartan suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Tasosartan DMF (Drug Master File) is a document detailing the whole manufacturing process of Tasosartan active pharmaceutical ingredient (API) in detail. Different forms of Tasosartan DMFs exist exist since differing nations have different regulations, such as Tasosartan USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Tasosartan DMF submitted to regulatory agencies in the US is known as a USDMF. Tasosartan USDMF includes data on Tasosartan's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Tasosartan USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Tasosartan suppliers with USDMF on PharmaCompass.
Tasosartan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tasosartan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tasosartan GMP manufacturer or Tasosartan GMP API supplier for your needs.
A Tasosartan CoA (Certificate of Analysis) is a formal document that attests to Tasosartan's compliance with Tasosartan specifications and serves as a tool for batch-level quality control.
Tasosartan CoA mostly includes findings from lab analyses of a specific batch. For each Tasosartan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tasosartan may be tested according to a variety of international standards, such as European Pharmacopoeia (Tasosartan EP), Tasosartan JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tasosartan USP).
LOOKING FOR A SUPPLIER?
